Strategic partnerships Exogene has a recent strategic collaboration with Immunocore to engineer T-cell receptors using AI, indicating a clear appetite for co-development and collaboration with established biotechs. Potential sales angle: offer AI-driven discovery services, data collaboration, or joint development partnerships to accelerate TCR-based therapies.

AI driven platform The company emphasizes a proprietary lab-in-the-loop AI platform for designing multi-specific immune engager drugs targeting peptide-HLA antigens. Potential sales angle: pitch AI consulting, model validation services, data generation partnerships, and wet-lab integration tools to enhance internal R&D productivity.

Early stage funding With funding of around $2.3M and a recent revenue of zero to one million, Exogene is in an early-stage growth phase and actively building its technical stack and datasets. Potential sales angle: provide early-stage CRO services, pilot project support, lab instrumentation, and data platform enhancements to scale from pilot to clinical development.

Oxford ecosystem Based in Oxford and focused on TCR discovery and cell therapies, Exogene leverages a strong academic and biotech cluster. Potential sales angle: propose collaboration with regional pharma, access to academic networks, technology licensing, and co-development with nearby contract research providers.

Commercial readiness The company aims to partner with pharma and biotech firms to discover TCRs and develop its own therapies for out-licensing, signaling openness to external partnerships. Potential sales angle: present as a partner for milestone-based programs, out-licensing opportunities, and co-development deals that align with Exogene’s strategic goals.